TNF and inflammatory bowel disease: In patients with a previously or simultaneously diagnosed IBD at the onset of AP, active IBD was reported in 179 out of 361 patients (49.6%); ongoing therapies included 5-ASA (5-aminosalicylic acid) in 153 (42.4%), AZA/6-MP (6-mercaptopurine) in 172 (47.6%), steroids in 48 (13%), and anti-TNF in 57 (15.5%) cases.